Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China

References

• Sung H, Ferlay J, Siegel RL, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3): 209–249.
   PubMed Web of Science ®Google Scholar
• Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25(1):S18–S30.
   PubMedGoogle Scholar
• Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664–672.
   PubMed Web of Science ®Google Scholar
• Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5(1):26–38.
   PubMed Web of Science ®Google Scholar
• CSCO. Guidelines of Chinese Society of Clinical Oncology (CSCO) for small-cell lung cancer. Beijing: CSCO, People’s Medical Publishing House; 2020.
   Google Scholar
• Song P-F, Xu N, Li Q. Efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133–11143.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al., Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021;125(3): 366–371.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–249.
   PubMed Web of Science ®Google Scholar
• Kwok G, Yau TCC, Chiu JW, et al. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777–2789.
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al., Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results From the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4): 618–627.
   PubMed Web of Science ®Google Scholar
• Smith KM, Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2018;18(7):611–618.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895.
   PubMed Web of Science ®Google Scholar
• Ready N, Farago AF, de Braud F, et al., Third-line nivolumab monotherapy in recurrent SCLC: checkMate 032. J Thorac Oncol. 2019;14(2): 237–244.
   PubMed Web of Science ®Google Scholar
• Rui M, Wang Y, Fei Z, et al., Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3): 373–380.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.
   PubMed Web of Science ®Google Scholar
• Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations 2020. Beijing: China Market Press; 2020.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al., Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1): 9.
   PubMed Web of Science ®Google Scholar
• Smare C, Dave K, Juarez-Garcia A, et al. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. J Med Econ. 2021;24(1):1124–1133.
   PubMed Web of Science ®Google Scholar
• Shi G, Park SH, Ren H, et al. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. J Med Econ. 2018;21(12):1150–1158.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non–small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203.
   PubMed Web of Science ®Google Scholar
• Rui M, Li H. Cost-effectiveness of osimertinib vs docetaxel-bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non–small cell lung cancer in China. Clin Ther. 2020;42(11):2159–70.e6.
   PubMed Web of Science ®Google Scholar
• Lu S, Yu Y, Fu S, et al. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLOS ONE. 2018;13(10):e0205827.
   PubMed Web of Science ®Google Scholar
• Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2021;22(1):1–7.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Region Health Eur. 2021;3:100060.
   PubMedGoogle Scholar
• Li Y, Sun Z, Sun W, et al. Effectiveness and safety of anlotinib monotherapy for patients with extensive-stage small-cell lung cancer who progressed to chemotherapy: a real-world exploratory study. Clin Med Insights Oncol. 2022;16:11795549211067184.
   Web of Science ®Google Scholar
• Gao X, Peng L, Zhang L, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. J Cancer Res Clin Oncol. 2021;148(10):2661–2671.
   PubMed Web of Science ®Google Scholar
• Schmid S, Mauti L, Friedlaender A, et al. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunol Immunother. 2020;69:1605–1613.
   PubMed Web of Science ®Google Scholar
• Stratmann JA, Timalsina R, Atmaca A, et al. Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis. Therap Adv Med Oncol. 2022;14:17588359221097191.
   Web of Science ®Google Scholar
• Roth JA, Yuan Y, Othus M, et al. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. J Med Econ. 2021;24(1):79–86.
   PubMed Web of Science ®Google Scholar
• Gong J, Wan Q, Shang J, et al. Cost-effectiveness analysis of anlotinib as third- or further-line treatment for relapsed Small Cell Lung Cancer (SCLC) in China. Adv Ther. 2021;38(10):5116–5126.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Pilotto S, Caccese M, et al. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis. 2018;10(Suppl 13):S1564–80.
   PubMedGoogle Scholar
• Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31–S41.
   PubMedGoogle Scholar
• Onoi K, Chihara Y, Uchino J, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020;9(5):1362.
   PubMed Web of Science ®Google Scholar
• Chen J, Qi Y, Wampfler JA, et al. Effect of cigarette smoking on quality of life in small cell lung cancer patients. Eur J Cancer. 2012;48(11):1593–1601.
   PubMed Web of Science ®Google Scholar